Peter Attia on libido: what TRT advice holds up to scrutiny

What did @thebossticks actually say?

The video summarizes Peter Attia's position on libido from his podcast, episode 603. The creator claims women respond well to "intranasal testosterone" for low desire, that an "intravaginal spray of testosterone increases orgasm," and that men's libido is driven by systemic testosterone levels. Treatment, they say, should follow a cluster of symptoms plus lab findings.

To be fair, this is a condensed clip of someone else's clinical framework, not original medical advice. The creator is essentially reporting Attia's views. That context matters when evaluating accuracy, because some nuance inevitably gets lost in a 60-second TikTok summary.

Does the science back this up?

Partially, yes, but the confidence level varies quite a bit depending on which specific claim you're examining. Some of this is well-supported. Some of it is based on small, preliminary studies that don't yet justify the certainty in the creator's tone.

On intranasal testosterone for women: there is real clinical data here. A randomized trial by Tuiten et al. (2011, Journal of Sexual Medicine) demonstrated that sublingual and intranasal testosterone formulations produced rapid central arousal effects in women with hypoactive sexual desire disorder (HSDD). The rapid-onset mechanism via nasal mucosa bypassing first-pass metabolism is pharmacologically plausible. However, no FDA-approved intranasal testosterone product for women currently exists in the United States, which is a significant omission from the video.

On intravaginal testosterone increasing orgasm: the evidence base here is thinner. Studies like Witherby et al. (2011, Journal of Sexual Medicine) showed localized benefits for genitourinary symptoms, but orgasm-specific outcomes are less consistently demonstrated across trials. The claim is not wrong, but it is stated with more certainty than the literature warrants.

On men and systemic testosterone: this is the most well-established part of the video. The relationship between low serum testosterone and symptoms like reduced libido, energy, and mood is supported by decades of endocrinology research, including the landmark Testosterone Trials (Snyder et al., 2016, NEJM).

What did they get wrong (or right)?

The symptom-plus-labs framework the creator describes, "low levels of testosterone coupled with some semblance of what the symptoms are," is actually the correct clinical standard. The Endocrine Society guidelines explicitly recommend against treating biochemical findings alone. So that part is right, and it's a point that often gets lost in testosterone marketing.

What they got wrong, or at least incomplete: describing intranasal testosterone as "really potent" for women without noting there is no approved product in the US creates a practical gap for viewers. Anyone hearing this who seeks treatment may not understand they're entering off-label territory. Off-label use is legal and common, but patients deserve to know that.

The orgasm claim for intravaginal testosterone is stated as fact when it should carry a qualifier. Localized testosterone can improve sexual function broadly, but the specific orgasm-enhancement framing outpaces the evidence. It is not false, but it is not settled science.

Credit where it's due: framing libido as complicated and not just hormonal is an honest and accurate starting point that many hormone-focused creators skip entirely.

What should you actually know?

If you're a woman experiencing low desire, testosterone is a legitimate clinical option worth discussing with a provider, but the conversation should include that you're likely looking at compounded or off-label formulations in the US. The Endocrine Society and ISSWSH both acknowledge testosterone therapy for HSDD in postmenopausal women, but guidance for premenopausal women is less established.

For men, the symptom-plus-labs approach is the right call. Testosterone testing alone tells you very little. Free testosterone, SHBG levels, and symptom burden all matter. If a provider wants to treat a number without asking about how you feel, that is a red flag.

• No intranasal testosterone product is FDA-approved for women in the United States as of 2024.
• Intravaginal testosterone is primarily studied for genitourinary syndrome of menopause, not orgasm enhancement specifically.
• Testosterone therapy for women remains off-label in the US, though it has regulatory approval in some other countries.
• The Testosterone Trials (Snyder et al., NEJM 2016) remain the most rigorous data on testosterone therapy in older men with low levels.